Factors Associated with Initial or Subsequent Choice of Biologic Disease Modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis

被引：0
|
作者：
Jin, Yinzhu [1 ]
Desai, Rishi J. [1 ]
Liu, Jun [1 ]
Choi, Nam-Kyong [1 ]
Kim, Seoyoung [1 ,2 ,3 ]
机构：
[1] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[3] Harvard Med Sch, Boston, MA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
基金：
新加坡国家研究基金会;
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3094
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Which Are The Most Common Disease Modifying Antirheumatic and Biologic Treatment Pathways For Rheumatoid Arthritis Patients?
    Pedro, Sofia
    Wolfe, Frederick
    O' Dell, James
    Michaud, Kaleb
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S721 - S721
  • [42] Factors predicting addition of disease-modifying antirheumatic drugs after initial methotrexate monotherapy in patients with rheumatoid arthritis
    Takashi Yamaguchi
    Noriko Kohyama
    Miki Takenaka
    Takahiro Okada
    Tatsuya Kurihara
    Kosuke Sakurai
    Yusuke Miwa
    Mari Kogo
    Clinical Rheumatology, 2021, 40 : 2657 - 2663
  • [43] Factors predicting addition of disease-modifying antirheumatic drugs after initial methotrexate monotherapy in patients with rheumatoid arthritis
    Yamaguchi, Takashi
    Kohyama, Noriko
    Takenaka, Miki
    Okada, Takahiro
    Kurihara, Tatsuya
    Sakurai, Kosuke
    Miwa, Yusuke
    Kogo, Mari
    CLINICAL RHEUMATOLOGY, 2021, 40 (07) : 2657 - 2663
  • [44] DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARD) IN THE TREATMENT OF PATIENTS WITH RHEUMATOID-ARTHRITIS
    HALBERG, P
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1986, : 55 - 57
  • [45] Predictors of effectiveness of biologic disease-modifying antirheumatic drugs (bDMARD) in the treatment of psoriatic arthritis
    Brandao, Natalia Dias
    Morgado, Marina
    Oliveira, Gerusa A.
    Acurcio, Francisco de Assis
    Guerra Junior, Augusto Afonso
    Alvares-Teodoro, Juliana
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 170 - 171
  • [46] CHANGING PATTERN OF THE USE OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS
    Sanchez-Piedra, Carlos
    Prior-Espanol, Agueda
    Freire Gonzalez, Mercedes
    Colazo, Maria
    Ruiz-Montesinos, Dolores
    Perez-Vera, Yanira
    Ortiz, Ana
    Bustabad, Sagrario
    Vela-Casasempere, Paloma
    Rojas-Gimenez, Marta
    Sanchez-Alonso, Fernando
    Diaz-Gonzalez, Federico
    Jesus Gomez-Reino, Juan
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1151 - 1152
  • [47] Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
    Xia, Yunfei
    Yin, Rulan
    Fu, Ting
    Zhang, Lijuan
    Zhang, Qiuxiang
    Guo, Genkai
    Li, Liren
    Gu, Zhifeng
    PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 735 - 742
  • [48] TREATMENT OF RHEUMATOID-ARTHRITIS WITH DISEASE MODIFYING ANTIRHEUMATIC DRUGS - CURRENT CONCEPTS AND PERSPECTIVES
    WOLLENHAUPT, J
    LANGER, HE
    WIENER MEDIZINISCHE WOCHENSCHRIFT, 1990, 140 (12) : 324 - 333
  • [49] A Quality Improvement Approach to Rheumatoid Arthritis Management With Biologic Disease-Modifying Antirheumatic Drugs: Assessing Variability in a Treatment Pathway
    Dave, Amish J.
    Tory, Heather O.
    Awosogba, J. Adebukola
    Coblyn, Jonathan S.
    Bermas, Bonnie
    Solomon, Daniel H.
    Desai, Sonali P.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2017, 23 (01) : 66 - 69
  • [50] Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
    Emery, Paul
    Sebba, Anthony
    Huizinga, Tom W. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (12) : 1897 - 1904
12345